Web semineri
Breaking down barriers: Why early commercialization planning is key to a successful market entry strategy
Regulatory approval is not the finish line. It is the beginning of the commercialization journey.
Join Cencora experts on Thursday, June 18, 2026, at 11:00 am ET, for a moderated discussion on why early commercialization planning matters, and how emerging biopharma companies can make smarter development and commercialization decisions to support successful market entry and long-term product success. When commercialization planning starts too late, the consequences can surface quickly: evidence gaps, misaligned comparators, limited reimbursement potential, and reduced strategic flexibility. Our experts will explore why commercialization planning should begin in phase 2 and phase 3, not at launch.
Join Cencora experts on Thursday, June 18, 2026, at 11:00 am ET, for a moderated discussion on why early commercialization planning matters, and how emerging biopharma companies can make smarter development and commercialization decisions to support successful market entry and long-term product success. When commercialization planning starts too late, the consequences can surface quickly: evidence gaps, misaligned comparators, limited reimbursement potential, and reduced strategic flexibility. Our experts will explore why commercialization planning should begin in phase 2 and phase 3, not at launch.
Learn how companies can better align evidence generation, patient population strategy, and go-to-market planning with market access expectations.
Key highlights
Attendees will leave with practical perspectives on how to identify risk earlier, inform development decisions, and strengthen readiness for launch. The session will conclude with a live Q&A.
Moderator:
Samantha Gleason, Global Pharmaceutical Product Launch Lead, Cencora
Speakers:
Kim Riggs, Vice President, Commercialization Strategy & Access Solutions, Cencora
Nancy Young, Vice President, Commercialization, Cencora
- How to align evidence planning with both regulatory and payer expectations.
- Why patient population and label strategy can directly influence access and reimbursement.
- How early comparator strategy and stakeholder engagement can reduce downstream risk.
- Which operational and go-to-market decisions can affect uptake, access, and long-term commercial performance.
Attendees will leave with practical perspectives on how to identify risk earlier, inform development decisions, and strengthen readiness for launch. The session will conclude with a live Q&A.
Moderator:
Samantha Gleason, Global Pharmaceutical Product Launch Lead, Cencora
Speakers:
Kim Riggs, Vice President, Commercialization Strategy & Access Solutions, Cencora
Nancy Young, Vice President, Commercialization, Cencora
